By adjusting the secretion of cytokines related to inflammation and angiogenesis and inhibiting the level of NF-κB p65 in the xenograft microenvironment, RosA could effectively inhibit tumor growth and had fewer toxic effects. RosA was a potential drug for the treatment of HCC. Here, NFKB1 is linked to hepatocellular carcinoma.